Share price shock at Siemens Energy! What are BioNTech and Cardiol Therapeutics doing?

Cardiol Therapeutics: Next top news in June?

The Cardiol Therapeutics share price has more than doubled this year, making it one of the top performers in the biotech sector in 2024. It is currently trading at USD 2.18, and analysts see even more potential. The experts at Canaccord recommend buying the shares of the specialist in cardiovascular diseases with a price target of USD 6. New study data, due to be published at the beginning of June, could trigger the next share price jump. The Company confirmed the schedule again on Tuesday.

Cardiol reported that the Phase II study to assess the effects of CardiolRx™ on myocardial regeneration in patients with acute myocarditis ("ARCHER") was the subject of a presentation at the World Congress on Acute Heart Failure 2024 in Lisbon. Carsten Tschöpe from the Berlin Institute of Health Research at Charité presented the baseline data of the first 50 patients randomized in the ARCHER study. From Cardiol's perspective, the cardiology community is very interested in the novel approaches for the treatment of acute myocarditis, for which there are currently no therapies approved by the regulatory authorities in Europe and the US. The Company also stated that patient recruitment is progressing rapidly.

Cardiol CEO David Elsley stated: "We are pleased to report that the ARCHER study has now reached over 85% of its target enrollment. We anticipate that the results of the ARCHER study will contribute to a better understanding of the therapeutic potential of CardiolRx™ and complement our already advanced Phase II MAvERIC-Pilot study in patients with recurrent pericarditis." Cardiol has again announced top-line results for the Phase II MAvERIC-Pilot study for early June 2024.

The fact that Cardiol's share price is not showing any weakness ahead of the important data is a positive signal.

BioNTech: How analysts are reacting to the quarterly figures

BioNTech shareholders have been waiting for a positive signal for some time. The stock is trading at USD 92, well below its all-time high of USD 390 from 2021. The recently published quarterly figures have also failed to give the share price any new impetus. Analysts are also cautious. Since last week, there have only been "Hold" recommendations.

BioNTech did not meet Goldman Sachs' expectations with its latest quarterly figures. According to the analysts, sales and profits were lower than expected. They, therefore, reduced the price target to USD 90. UBS is currently the most optimistic, although the analysts' fair value of USD 101 also offers only manageable upside potential. The experts consider BioNTech's oncology pipeline to be attractive. However, research takes time, and the share price will only likely benefit from this in the longer term. Deutsche Bank's price target for BioNTech shares is USD 95, and Jefferies believes the share price could reach USD 100.

Siemens Energy: Share price soon -50%?

Bernstein Research caused a stir on Tuesday with a possible halving of the Siemens Energy share price. The analysts pointed to risks in the US. An election victory for Donald Trump could lead to noticeable cuts in the German company's US business in the medium term. The Republican presidential candidate recently announced at a fundraising event that he would strengthen the domestic oil industry if he won the election. According to this, the promotion of renewable energies is to be massively curtailed. This is also likely to apply to offshore wind energy. Siemens Gamesa is a major player in this segment. Bernstein Research, therefore, rates the Siemens Energy share as "Underperform". The target price is EUR 12. However, the bulls are not letting this unsettle them at the moment. Yesterday alone, the share gained more than 1% and reached a new high for the year of EUR 24.51.

Incidentally, Goldman Sachs is Siemens Energy's biggest fan among analysts. After last week's quarterly figures, it raised its price target from EUR 27 to EUR 32.70 and confirmed its "Buy" recommendation. The majority of analysts are also positive.

Siemens Energy will report on its performance in the third quarter in August.

Siemens Energy seems to have recovered from the past year's problems. Currently, a reference to the potential negative effects of a Donald Trump election victory is not enough to interrupt the stock's momentum. The Cardiol Therapeutics share continues to demonstrate strength, and analysts see plenty of room for growth. A short-term price jump is not expected for BioNTech, even though the long-term prospects appear positive.